Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 158 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016', provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted pipeline therapeutics. 

The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
- The report reviews Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Overview 8
Therapeutics Development 9
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Stage of Development 9
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Therapy Area 10
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Indication 11
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Companies 16
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Universities/Institutes 25
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Therapeutics Assessment 27
Assessment by Monotherapy/Combination Products 27
Assessment by Mechanism of Action 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Companies Involved in Therapeutics Development 33
Abeome Corporation 33
Alnylam Pharmaceuticals, Inc. 34
AlphaMab Co., Ltd 35
AstraZeneca Plc 36
Aurigene Discovery Technologies Limited 37
BeiGene, Ltd. 38
Bristol-Myers Squibb Company 39
CytomX Therapeutics, Inc. 40
Eli Lilly and Company 41
F. Hoffmann-La Roche Ltd. 42
Genosco 43
ImmunoCellular Therapeutics, Ltd. 44
Immunocore Limited 45
IO Biotech ApS 46
Kadmon Corporation, LLC 47
MedImmune, LLC 48
Merck KGaA 50
Novartis AG 51
PsiOxus Therapeutics Limited 52
Regeneron Pharmaceuticals, Inc. 53
Shanghai Henlius Biotech Co., Ltd. 54
Sorrento Therapeutics, Inc. 55
Sutro Biopharma, Inc. 56
Theravectys SA 57
Tikcro Technologies, Ltd. 58
ViiV Healthcare Limited 59
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Drug Profiles 60
ALN-PDL - Drug Profile 60
Antibody to Inhibit PD-L1 for Oncology - Drug Profile 61
atezolizumab - Drug Profile 62
AUPM-327 - Drug Profile 73
avelumab - Drug Profile 74
Biologic to Inhibit PD-L1 for Immunology - Drug Profile 79
BMS-936559 - Drug Profile 80
CA-170 - Drug Profile 83
CBA-0710 - Drug Profile 85
CX-072 - Drug Profile 86
dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 87
durvalumab - Drug Profile 88
durvalumab + gefitinib - Drug Profile 97
durvalumab + IMCgp-100 + tremelimumab - Drug Profile 98
durvalumab + MEDI-0680 - Drug Profile 99
durvalumab + MEDI-6383 - Drug Profile 100
durvalumab + MEDI-9447 - Drug Profile 101
durvalumab + monalizumab - Drug Profile 102
durvalumab + tremelimumab - Drug Profile 103
GNS-1480 - Drug Profile 106
HLX-10 - Drug Profile 107
HLX-20 - Drug Profile 108
IO-103 - Drug Profile 109
KD-033 - Drug Profile 110
KN-035 - Drug Profile 111
LY-3300054 - Drug Profile 112
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 113
Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 114
Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 115
Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 116
Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile 117
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 118
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 119
Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 120
Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile 121
Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology - Drug Profile 122
MSB-002 - Drug Profile 123
Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile 124
Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile 125
STIA-1011 - Drug Profile 126
STIA-1012 - Drug Profile 127
STIA-1014 - Drug Profile 128
STIA-1015 - Drug Profile 129
Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile 130
Synthetic Peptide 2 to Inhibit PDL1 for Oncology - Drug Profile 131
Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 132
Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 133
Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 134
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Dormant Projects 135
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Discontinued Products 136
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Featured News & Press Releases 137
Appendix 153
Methodology 153
Coverage 153
Secondary Research 153
Primary Research 153
Expert Panel Validation 153
Contact Us 153
Disclaimer 154

List of Tables

Number of Products under Development for, H1 2016 13
Number of Products under Development by Therapy Area, H1 2016 14
Number of Products under Development by Indication, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Number of Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Products under Development by Companies, H1 2016 (Contd..3) 24
Products under Development by Companies, H1 2016 (Contd..4) 25
Products under Development by Companies, H1 2016 (Contd..5) 26
Products under Development by Companies, H1 2016 (Contd..6) 27
Products under Development by Companies, H1 2016 (Contd..7) 28
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Products under Investigation by Universities/Institutes, H1 2016 30
Assessment by Monotherapy/Combination Products, H1 2016 31
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Pipeline by Abeome Corporation, H1 2016 37
Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 38
Pipeline by AlphaMab Co., Ltd, H1 2016 39
Pipeline by AstraZeneca Plc, H1 2016 40
Pipeline by Aurigene Discovery Technologies Limited, H1 2016 41
Pipeline by BeiGene, Ltd., H1 2016 42
Pipeline by Bristol-Myers Squibb Company, H1 2016 43
Pipeline by CytomX Therapeutics, Inc., H1 2016 44
Pipeline by Eli Lilly and Company, H1 2016 45
Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 46
Pipeline by Genosco, H1 2016 47
Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016 48
Pipeline by Immunocore Limited, H1 2016 49
Pipeline by IO Biotech ApS, H1 2016 50
Pipeline by Kadmon Corporation, LLC, H1 2016 51
Pipeline by MedImmune, LLC, H1 2016 52
Pipeline by Merck KGaA, H1 2016 54
Pipeline by Novartis AG, H1 2016 55
Pipeline by PsiOxus Therapeutics Limited, H1 2016 56
Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 57
Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 58
Pipeline by Sorrento Therapeutics, Inc., H1 2016 59
Pipeline by Sutro Biopharma, Inc., H1 2016 60
Pipeline by Theravectys SA, H1 2016 61
Pipeline by Tikcro Technologies, Ltd., H1 2016 62
Pipeline by ViiV Healthcare Limited, H1 2016 63
Dormant Projects, H1 2016 139
Discontinued Products, H1 2016 140